In a finding with implications for one of the most promising cutting-edge medical treatments, researchers evaluated several ...
WuXi AppTec, the Shanghai-based biotech giant, has sold its South Philly-based WuXi Advanced Therapies contract manufacturing ...
BIAL, a hundred-year-old innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, announced that the first patient has completed the full dose regimen in the ACTIVATE ...
Enliven Therapeutics' ELVN-001 shows promising results for CML patients. Click here to read what makes ELVN stock a ...
Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced that Chief Executive Officer, Madan Jagasia, M.D., will present at ...
Boston-based Dana-Farber Cancer Institute has launched the Center for RAS Therapeutics, aiming to study and develop drug therapies for RAS-driven cancers.
My darling mum Barbara looked like an old-fashioned movie star. With her dramatic eye make-up and perfectly coiffed dark hair ...
Scientists from KAIST have developed technology that can transform cancer cells into normal cells, offering a potentially new ...
Thirty-one members of the University of Chicago faculty have received distinguished service professorships or named ...
Purpose. Unlabeled uses of factor VIIa (recombinant) in pediatric patients are reviewed. Summary. Factor VIIa (recombinant) is currently approved for the treatment and prevention of bleeding in ...